Focus: Cipher Pharmaceuticals is a public specialty pharma company headquartered in Mississauga, ON, focused on small-molecule therapeutics with a portfolio concentrated in neurology and dermatology.
Profile data last refreshed 22h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Cipher Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Lead revenue driver (99% of total), KIT receptor inhibitor, patent-protected for 16+ years.
Help build intelligence for Cipher Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Cipher Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Legacy lipid-lowering asset with minimal revenue contribution; approaching loss of exclusivity.
Lice and mite treatment at peak lifecycle; patent protection through 2033; minimal revenue footprint.
Extended-release opioid analgesic with near-term LOE risk and negligible revenue contribution.
Emerging CSF-1R inhibitor in growth phase with long patent runway to 2045; emerging upside candidate beyond QINLOCK.
2 discontinued, 0 duplicate formulations not shown
This analyst just raised his price target on Cipher Pharma - Cantech Letter
This analyst just raised his price target on Cipher Pharma Cantech Letter
8-K Filing: Profound Medical Corp. (PROF) (CIK 0001628808) — EXHIBIT 99.1
EXHIBIT 99.1
Cipher Pharmaceuticals Schedules Q1 2026 Earnings Release and Conference Call - Yahoo Finance
Cipher Pharmaceuticals Schedules Q1 2026 Earnings Release and Conference Call Yahoo Finance
CaryHealth Launches Direct-to-Patient Program for Cipher Pharmaceuticals’ Natroba (spinosad) - Business Wire
CaryHealth Launches Direct-to-Patient Program for Cipher Pharmaceuticals’ Natroba (spinosad) Business Wire
No open positions listed yet. Check their careers page directly.
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Hyaluronic Acid Sodium Salt 0.2% Gel in the Treatment of a Recalcitrant Distal Leg Ulcer: A Case Report.
Comparative pharmacokinetic profiles of a novel isotretinoin formulation (isotretinoin-Lidose) and the innovator isotretinoin formulation: a randomized, 4-treatment, crossover study.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo